CeriBell, Inc. (NASDAQ:CBLL) Given Consensus Recommendation of "Buy" by Brokerages

Key Points

• CeriBell, Inc. has received a consensus rating of "Buy" from eight brokerages, with an average 12-month price target of $32.14.
• The company's recent earnings report showed a narrower loss than expected, posting an EPS of ($0.38) against an estimate of ($0.40), and revenue exceeded forecasts at $21.20 million.
• Insider transactions included significant sales of stock by the Director and CEO, indicating a 3.12% and 52.70% decrease in their respective ownership positions.

Shares of CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) have been given an average rating of "Buy" by the eight research firms that are covering the firm, MarketBeat.com reports. Eight analysts have rated the stock with a buy rating. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $32.1429.

Separately, BTIG Research began coverage on shares of CeriBell in a report on Tuesday, June 24th. They issued a "buy" rating and a $30.00 price objective on the stock.

CeriBell Stock Down 4.3%

CBLL stock traded down $0.53 during mid-day trading on Monday, hitting $11.80. 273,127 shares of the company were exchanged, compared to its average volume of 304,335. The company has a debt-to-equity ratio of 0.11, a quick ratio of 12.91 and a current ratio of 13.31. The firm has a market cap of $432.59 million and a P/E ratio of -3.95. The firm's 50 day simple moving average is $14.24 and its 200 day simple moving average is $17.06. CeriBell has a 1-year low of $10.01 and a 1-year high of $32.75.

CeriBell (NASDAQ:CBLL - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.40) by $0.02. CeriBell had a negative net margin of 63.83% and a negative return on equity of 48.42%. The company had revenue of $21.20 million for the quarter, compared to the consensus estimate of $20.52 million. CeriBell has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that CeriBell will post -2.46 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Xingjuan Chao sold 25,000 shares of CeriBell stock in a transaction that occurred on Monday, July 7th. The shares were sold at an average price of $17.70, for a total value of $442,500.00. Following the sale, the chief executive officer directly owned 776,022 shares in the company, valued at $13,735,589.40. This trade represents a 3.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Rebecca B. Robertson sold 11,188 shares of the business's stock in a transaction on Wednesday, June 18th. The stock was sold at an average price of $17.85, for a total transaction of $199,705.80. Following the transaction, the director owned 10,042 shares in the company, valued at approximately $179,249.70. The trade was a 52.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 64,499 shares of company stock worth $1,126,402 over the last quarter. 20.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On CeriBell

Institutional investors have recently added to or reduced their stakes in the company. KLP Kapitalforvaltning AS acquired a new position in CeriBell during the first quarter worth $36,000. Tower Research Capital LLC TRC acquired a new position in CeriBell during the fourth quarter worth $37,000. BNP Paribas Financial Markets acquired a new position in CeriBell during the fourth quarter worth $43,000. Tower Research Capital LLC TRC increased its holdings in CeriBell by 353.8% during the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company's stock worth $43,000 after buying an additional 1,801 shares during the last quarter. Finally, Ameritas Investment Partners Inc. increased its holdings in CeriBell by 97.5% during the second quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company's stock worth $48,000 after buying an additional 1,256 shares during the last quarter.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.